Antibiotic resistance transformation in community-acquired urinary infections

被引:16
作者
Garín, JAL [1 ]
Santos, JP [1 ]
Costa, MS [1 ]
Alvarez, CS [1 ]
Gelabert-Mas, A [1 ]
机构
[1] UAB, Hosp Mar, Serv & Catedra Urol, Barcelona 08003, Spain
来源
REVISTA CLINICA ESPANOLA | 2005年 / 205卷 / 06期
关键词
urinary tract infections; community; antimicrobial resistance;
D O I
10.1157/13076148
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To detect the prevalence of uropathogens in community-adquired urinary tract infection in our environment, and the degree of sensitivity to antibiotics used as empirical treatment. Patients and method. Retrospective longitudinal study on 16,392 consecutive urine cultures collected in the emergency department of Hospital del Mar, between January 1997 and December 2001. Resistance rates were compared through variance analysis. Results. 8,743 urine cultures with significant count were obtained. 6,062 Escherichia coli (69.3%), 517 Proteus mirabilis (5.9%) and 390 Klebsiella pneumoniae (4.5%) were identified. Escherechia coli showed progressive growth rate and significant resistances to most of antibiotics evaluated, especially to quinolones which came close to 30%. Fosfomycin showed the least resistance rate (0.9%) and remained stable along the years studied. Conclusions. These results suggest that higher rate of resistance to quinolones does not advise its use as empirical in community-acquired urinary tract infection treatment in our environment. According to our experience, fosfomycin can be an excellent option for cystitis treatment in patients without risk factors, while for the treatment of parenchymatous urinary tract infection, complicated urinary tract infections, and urinary tract infections associated to risk factors, preference could be second or third generation oral cephalosporins, or amoxicillin-clavulanic acid.
引用
收藏
页码:259 / 264
页数:6
相关论文
共 29 条
[1]   THE EMERGENCE OF HIGHLY FLUOROQUINOLONE-RESISTANT ESCHERICHIA-COLI IN COMMUNITY-ACQUIRED URINARY-TRACT INFECTIONS [J].
AGUIAR, JM ;
CHACON, J ;
CANTON, R ;
BAQUERO, F .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 29 (03) :349-350
[2]  
Alos Cortes J I, 1997, Rev Clin Esp, V197, P167
[3]  
ALOS JI, 1993, MED CLIN-BARCELONA, V101, P87
[4]  
BAQUERO F, 1997, REV ESP QUIM, V10, P303
[5]  
Courvalin P., 1992, ASM NEWS, V58, P368, DOI DOI 10.1111/J.1469-0691.1996.TB00872.X
[6]  
DALET F, 1996, INFECCIONES URINARIA
[7]   RISK-FACTORS FOR ACQUISITION OF URINARY-TRACT INFECTIONS CAUSED BY CIPROFLOXACIN RESISTANT ESCHERICHIA-COLI [J].
ENA, J ;
AMADOR, C ;
MARTINEZ, C ;
DELATABLA, VO .
JOURNAL OF UROLOGY, 1995, 153 (01) :117-120
[8]   Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centres by three methods [J].
Fuchs, PC ;
Barry, AL ;
Brown, SD .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (01) :137-140
[9]   In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: A Spanish multicenter study [J].
Garcia-Rodriguez, JA ;
Martin, IT ;
Baquero, F ;
Cisterna, R ;
Gobernado, M ;
Linares, F ;
Martin-Luengo, F ;
Piedrola, G .
JOURNAL OF CHEMOTHERAPY, 1997, 9 (06) :394-402
[10]   Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in The Netherlands [J].
Goettsch, W ;
van Pelt, W ;
Nagelkerke, N ;
Hendrix, MGR ;
Buiting, AGM ;
Petit, PL ;
Sabbe, LJM ;
van Griethuysen, AJA ;
de Neeling, AJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (02) :223-228